EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood

BMJ (Online)

Volumn 347, Issue 7922, 2013, Pages

  Doshi, Peter ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); DOCUMENT EXAMINATION; DRUG INDUSTRY; INFORMATION DISSEMINATION; LETTER; OFF LABEL DRUG USE; PRIORITY JOURNAL; RESPONSIBILITY;

CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG DISCOVERY; DRUG INDUSTRY; EUROPE; HUMANS; INFORMATION DISSEMINATION; OFF-LABEL USE; UNITED STATES;

EID: 84883238604     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f5164     Document Type: Letter

References (5)

1. O'Dowd A. Drug industry pledge on access to trial data is met with scepticism. BMJ 2013;347:f4829. (30 July.)
2. Thomas K. Drug companies promise more data transparency. New York Times 2013 Jul 24. www.nytimes.com/2013/07/25/business/drug-companies-promise-more- datatransparency. html.
3. Roche. Roche global policy on sharing of clinical trials data.http://roche-trials.com/dataSharingPolicy.action.
4. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475-8.
5. Zarin DA. Participant-level data and the new frontier in trial transparency. N Engl J Med 2013;369:468-9.